leadf
logo-loader
viewAequus Pharmaceuticals Inc.
(
TSX-V:AQSOTCQB:AQSZF
)

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye drops in Canada

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye disease.

Janzen telling Proactive this is the first of three products they hope to bring to market and he talks about the size of the market they are looking to try and grab a piece of.

Quick facts: Aequus Pharmaceuticals Inc.

Follow
TSX-V:AQS

Price: 0.125 CAD

Market Cap: $16.58 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

5 hours, 21 minutes ago

2 min read